Team

Co-Founder & Executive Chair

Dr Erin Gainer is a global leader and biopharma strategist in women’s health and rare diseases, having led multiple drug development programs and served as CEO and then Chair of the Board of HRA Pharma, culminating in a trade sale in 2022.
She is passionate about driving innovation to respond to unmet medical needs and is the author/inventor of dozens of peer-reviewed publications and patents. She currently advises life sciences companies and investors, serves as an independent director for public and private companies, and aims to accelerate innovation as a business angel and impact investor.
A graduate from Rice University and John Hopkins School of Public Health, Erin has a PhD in epidemiology from Paris-Sud University and a Global Executive MBA from INSEAD.

Co-Founder & Chief Scientific Officer

Dr. Mycielska graduated in Molecular Biology from Jagiellonian University, where she also earned her PhD. She completed her habilitation at the University of Regensburg.
Her research focuses on cancer cell metabolism and metabolite transport across cellular membranes, conducted at Jagiellonian University, Imperial College London, the Medical College of Georgia (USA), and the University of Regensburg.
Her major achievement is demonstrating the dependence of cancer cells on extracellular citrate and cloning the specific citrate transporter protein responsible for this process. She is the author of numerous publications in international journals and inventor on related patents. Her work has contributed to a deeper understanding of cancer metabolism and the identification of potential therapeutic targets.

Co-Founder & Head of Computational Biology

Prof. Dr. Miguel Rubi graduated in Physics from the Autonomous University of Barcelona, where he also obtained his PhD in statistical physics. He worked as a postdoctoral researcher at Leiden University.
Prof. Rubi is a specialist in computational biology, using models and simulations to study biological processes. He has made important contributions to the study of membrane transporters and ion channels, protein structure prediction, and cancer progression. His research has also improved understanding of how molecular chaperones help prevent neurodegenerative diseases, as well as the use of statistical methods and artificial intelligence in cancer research.
He has held several academic positions, including Onsager Professor at the Norwegian University of Science and Technology, Leverhulme Professor at Imperial College London, and Sandoval Vallarta Professor at Universidad Autónoma Metropolitana (Mexico).
Prof. Rubi has been awarded the Humboldt Research Award by the Alexander von Humboldt Foundation (Germany), the Leverhulme Prize (UK), and the Plus Ratio Quam Vis Medal by Jagiellonian University (Poland). He has also been appointed Doctor Honoris Causa by the Norwegian University of Science and Technology.